<DOC>
	<DOC>NCT02501330</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1. adverse drug reaction not expected from the LPD (unknown adverse drug reaction) 2. the incidence of adverse drug reactions in this surveillance 3. factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Safety And Efficacy Of Bosutinib</brief_title>
	<detailed_description>The patients should be registered by central registration system.</detailed_description>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<criteria>Chronic myelogenous leukemia patients resistant or intolerant to prior treatment there is no experience with this drug Patients with a history of hypersensitivity Women who may possibly be pregnant or become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug use investigation in Japan</keyword>
</DOC>